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Background. We developed a multicentric Swiss protocol for ABO-incompatible kidney transplantation including immuno-
adsorption column reuse. The aim of this study was to assess efficacy and safety of immunoadsorption column reuse in ABO-
incompatible kidney transplantation.Methods.Weperformed amulticentric prospective trial including all ABO-incompatible kid-
ney transplantations in Switzerland from 2005 to 2011. Patients received rituximab and standardized immunosuppression with
tacrolimus, mycophenolate mofetil, and steroids. Antigen-specific perioperative immunoadsorption was performed. Immuno-
adsorption columns were reused after restoration. Graft survival, patient survival, kidney function, rejections, number of columns,
adverse events after column reuse, and anti-A/anti-B antibody titers were assessed. Results. Seventy-one ABO-incompatible
patients underwent antigen-specific immunoadsorption and could be transplanted across the blood group barrier. Kaplan-
Meier estimates for both, patient-censored and death-censored graft survivals were both 97.2% at 5 years. Allograft function
was excellent with a mean estimated glomerular filtration rate of 54 mL per min after 1 year. The median number of pretransplant
immunoadsorptions was 5. All centers performed column reuse. A total of 394 immunoadsorption procedures were performed
with reused filters. Patient survival, graft survival, and adverse events did not differ when filters were reused. Column reuse resulted
in cost savings of 21,458 USD per patient. Conclusion.We have introduced a national protocol for ABO-incompatible kidney
transplantation including immunoadsorption column reuse. Column reuse was efficient and safe.
(Transplantation 2015;99: 1030–1035)The increasing discrepancy between patients on the waitinglist and transplanted kidneys has initiated innovative
strategies to decrease organ shortage. Regarding living donor
kidney transplantation sophisticated protocols to overcome
ABO incompatibility were introduced in the past.1 Initial at-
tempts have been made in the late 1980s in Japan. With im-
proved understanding of the mechanisms of accommodation
and antibody-mediated rejection (AMR) and progress in im-
munosuppression, the results have improved markedly, and
are nowadays only slightly inferior or comparable to those
of ABO-compatible kidney transplantation.2-5
However, the pretreatment of the recipient is elaborate and
expensive. Different techniques to remove the blood group
antibodies are used, such as the double filtration plasmaReceived 13 November 2013. Revision requested 11 December 2013.
Accepted 26 August 2014.
1 Department of Visceral and Transplantation Surgery, University Hospital Zurich,
Zurich, Switzerland.
2 Department of Nephrology, University Hospital Bern, Bern, Switzerland.
3 Department of Nephrology, University Hospital Geneva, Geneva, Switzerland.
4 Department of Nephrology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
5 Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
6 Department of Nephrology, University Hospital Basel, Basel, Switzerland.
The authors declare no funding or conflicts of interest.
M.S. participated in performance of the research, data analysis and writing ofthe
article. D.S. participated in performance of the research and data analysis. K.H.
1030 www.transplantjournal.com
Copyright © 2015 Wolters Kluwerexchange, regular therapeutic plasma exchange, and nonspe-
cific and specific immunoadsorptions.6,7 A major advantage
of specific immunoadsorption is the efficient depletion of cir-
culating blood group antibodies without considerable losses
of protective antibodies and other essential plasma constitu-
ents.8 On the other hand, this treatment is expensive if the
immunoadsorption columns are used only once as suggested
by the manufacturer.
In Switzerland, we have introduced ABO-incompatible
transplantation in 2005, and the involved transplantation
centers have agreed on a common protocol using specific
immunoadsorption to remove the blood group antibodies.
Because of the high costs for the immunoadsorption and ad-
ditional immunosuppressive medication, we have subse-
quently introduced a protocol to reuse the immunoadsorptionparticipated in the performance of the research and research design. U.H.-D.
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© 2015 Wolters Kluwer Schiesser et al 1031columns.9We report the results of the Swiss multicenter ABO-
incompatible kidney transplantation cohort with a focus on
safety and efficacy of the reuse of immunoadsorption columns.
MATERIALS AND METHODS
Patients
This is a multicenter prospective trial that included all pa-
tients from transplant centers performing ABO-incompatible
kidney transplantation in Switzerland from December 28,
2005 to December 31, 2011. A working group for ABO-
incompatible kidney transplantation has been established
with representants from all five Swiss transplant centers
performing ABO-incompatible kidney transplantation. The
working group agreed on one protocol for the desensitization
and immunosuppressive treatment. Each center obtained ap-
proval for the protocol by the respective local ethical commit-
tee (Ref. StV 11-2005). The workup of recipients and donors
was performed according to our national and center-specific
guidelines.
Male or female patients regardless of age and race, suffer-
ing from end-stage renal disease, and fulfilling the general
criteria for living donor kidney transplantationwere included
in the trial. First and repeated kidney transplantations were
accepted. All patients gave their written informed consent.
Patients were suitable for the protocol if they had a blood
group-incompatible living kidney donor with a current nega-
tive T-cell and B-cell CDC cross-match (XM) test.
Desensitization and Immunosuppression
A single dose of rituximab (375mg/m2) was given 4 weeks
before the transplantation. Maintenance immunosuppres-
sion with tacrolimus (0.1 mg/kg twice daily), mycophenolate
mofetil (1000 mg twice daily, 500 mg twice daily if body
weight was less than 50 kg), and prednisone (25 mg once
daily) was started before transplantation. Selective blood group
antibody removal was performed with a low-molecular car-
bohydrate column containing A or B blood group antigens
linked to a sepharose matrix (Glycosorb; Glycorex Transplan-
tation, Lund, Sweden). Apheresis sessions were performed daily
until the immunoglobulin (IgG) and isoagglutinin (IgM) anti-
body titers against donor erythrocytes were 1:8 or less. The
transplantation was then carried out the following day. With
each session, at least two plasma volumes were processed. At
the beginning of the study, a single dose of IVIG (0.5 g/kg
body weight) on day −1 was given; later, IVIG therapy was
discontinued. The participating centers were free to give an
induction therapy with 20 mg basiliximab on days 0 and 4.
Follow-Up
Blood group antibodies against donor erythrocytes were
measured daily for 2 weeks, weekly until day 31 and 3, 6,
and 12 months thereafter. At the beginning of study 3, pro-
phylactic apheresis sessions were scheduled after transplanta-
tion. Later, apheresis sessions were only performed on demand
in case of graft dysfunction and a titer increase greater than
1:8 within the first week or greater than 1:16 within the
second week after transplantation. A graft biopsy was per-
formed, and daily immunoadsorption or therapeutic plasma
exchange was started in these cases. An isolated increase of
blood group antibody titers in the absence of clinical signs
of graft dysfunction was not mandatory for the start of aphe-
resis sessions.Copyright © 2015 Wolters Kluwer HTarget tacrolimus trough levels were 8 to 10 ng/mL from
day −14 to 90, 6 to 8 ng/mL from day 90 to 365, and 4 to
6 ng/mL thereafter. Target mycophenolate mofetil trough
level was greater than 2 mg/mL. Steroids (methylpredniso-
lone intravenously and prednisone orally), 500 mg IV on
day 0, 250 mg IVon day 1, 100 mg IVon day 2, 50mg orally
from day 3 to 6, 0.5 mg/kg body weight orally from day 7
with a reduction by 5 mg every 2 weeks until 15 mg per
day, then by 2.5 mg every 2 weeks until a maintenance
dose of 0.1 mg/kg was given. Steroid withdrawal could be
considered if the 1-year protocol biopsy revealed no signs
of rejection.
Graft Biopsies
Protocol biopsies were performed at 12 months or more
frequent according to center policy. Diagnostic biopsies were
performed in case of otherwise not explained graft dysfunc-
tion using formalin fixation and fresh frozen technique.
Staining was performed according to previously described
procedures.10 Biopsies were judged according to the revised
Banff criteria 2007 and 2009.11,12
Treatment of Acute Rejection
Acute cellular rejection was treated according to local
practice with methylprednisolone pulses. In case of suspected
or biopsy-proven AMR methylprednisolone (0.5 g intrave-
nously on three consecutive days) was administered. Daily se-
lective immunoadsorption or therapeutic plasma exchange
and IVIG could be applied at the discretion of the treating
physician.
Detection of Anti–Human Leukocyte Antigen
Antibodies and Assignment as Human Leukocyte
Antigen–Donor-Specific Antibodies
All sera were tested for class I (i.e., human leukocyte
antigen [HLA]-A/B/C) and class II (i.e., HLA-DR/DQ/DP) anti-
HLA antibodies using single antigen flow bead assay on a
Luminex platform (LabScreen; OneLambda, Canoga Park,
CA). A positive result was defined as a baseline normalized
mean fluorescent intensity greater than 500. Donor specific-
ity of anti-HLA antibodies was determined by comparison
of the anti-HLA antibody specificities with the HLA typing
of the donor as previously reported.5 The CDC-XM assay
was performed as reported previously.13 No prospective flow
cytometry-XMwas performed. Typing of HLA-antigens was
determined by serology (A/B/DR) and/or by sequence specific
primer DNA typing (A/B/DR/DQ).
Detection of Blood Group Antibody Titers
Blood group antibody titers were determined against donor-
specific erythrocytes by the saline method (IgM) and the indi-
rect Coombs test (IgG) as described previously in detail.5
Regeneration of the Columns
Patients with filter reuse were analyzed in a subgroup (fil-
ter reuse group). Immunoadsorption columns were regener-
ated using solutions from Fresenius Medical Care (Redmond,
WA). Immediately after the immunoadsorption procedure,
the plasma was rinsed out of the column using 1000 mL
Buffer PA pH 7.0. After rinsing, the antibodies were eluted
with a citrate solution: 1000 mL eluate PA pH 2.2. After elu-
tion, the column was neutralized with 1,000 mL buffer PA
pH 7.0. Finally, the column (volume, 70 mL) was rinsedealth, Inc. All rights reserved.
TABLE 1.
IgM and IgG titers for the first use to the third reuse
IgG
IgG titer 1° use (N=57) 1° reuse (N=57) 2° reuse (N=28) 3° reuse (N=8)
0 43 (75.4%) 46 (80.7%) 22 (78.6%) 7 (87.5%)
1 1 (1.8%) 1 (1.8%) 1 (3.6%) 1 (12.5%)
2 5 (8.8%) 2 (3.5%) 2 (7.1%) 0 (0.0%)
4 2 (3.5%) 5 (8.8%) 3 (10.7%) 0 (0.0%)
8 5 (8.8%) 2 (3.5%) 0 (0.0%) 0 (0.0%)
16 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
32 1 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
64 0 (0.0%) 1 (1.8%) 0 (0.0%) 0 (0.0%)
Ranka 93.5 67.6 64.5 42.0
IgM
IgM titer 1° use (N=57) 1° reuse (N=57) 2° reuse (N=28) 3° reuse (N=8)
0 6 (10.5%) 19 (33.3%) 9 (32.1%) 6 (75.0%)
1 15 (26.3%) 15 (26.3%) 11 (39.3%) 0 (0.0%)
2 19 (33.3%) 18 (31.6%) 5 (17.9%) 2 (25.0%)
4 9 (15.8%) 2 (3.5%) 2 (7.1%) 0 (0.0%)
8 5 (8.8%) 1 (1.8%) 1 (3.6%) 0 (0.0%)
16 2 (3.5%) 1 (1.8%) 0 (0.0%) 0 (0.0%)
32 0 (0.0%) 1 (1.8%) 0 (0.0%) 0 (0.0%)
64 1 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Rankb 78.2 74.3 74.9 67.1
a PTrend=0.083 (Spearman ρ over the mean ranks).
b PTrend=0.333 (Spearman ρ over the mean ranks).
N (%) for columns.
There was no significant difference regarding filter efficacy. Fifty-seven filters were tested after the first
use and first reuse, 28 filters after the second reuse, and eight filters after the third reuse.
IgG, immunoglobulin G; IgM, immunoglobulin M.
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containing 0.04% polyhexamethylenebiguanide. The col-
umns were stored in the dark at +2°C to +8°C.
Evaluation of ColumnPerformance After Regeneration
In a subgroup of 57 columns, the performance of the col-
umn was systematically evaluated at the end of every im-
munoadsorption. Blood group antibody titers against the
donor’s blood group were estimated in the blood taken
10 min before the end of the procedure from the line immedi-
ately after the column (Table 1). Negative or low antibody ti-
ters indicate efficient antibody removal even at the end of
treatment and despite of reuse of the columns. One columnFIGURE 1. Patient-censored (A) and death-censored graft survivals (B)
Copyright © 2015 Wolters Kluwerrevealed a lack of efficacy after the first regeneration in the
ex vivo testing. The mean IgG titers of blood group A anti-
bodies were 1.6 after the first reuse (median, 0; range, 0 to
64) and 0.36 (median, 0; range, 0 to 4) after the second reuse.
Columnswere reused formaximally four times and remained
efficient even after multiple reuses. Immunoglobulin G levels
appeared to be lower than IgM titers.
Complications
Perioperative complications were graded according the
Clavien/Dindo classification.14 Infectious complications were
monitored throughout the whole follow-up period and graded
as severe, when a hospitalization was needed. BK and CMV
replication were monitored on a routine basis. The CMVdis-
ease was defined according to Ljungman et al.15
Statistics
Statistical analysis was performed using SPSS forWindows,
version 15 (SPSS Inc., Chicago, IL). Kaplan-Meier estimates
were calculated, Log rank test and chi-square test to compare
groups were applied as appropriate. A two-sided P value was
considered as statistically significant if less than 0.05.RESULTS
Patient Characteristics
From September 2005 until December 2011, a total of 80
patients with an ABO-incompatible donor recipient constel-
lationwere transplanted in five Swiss transplant centers using
a common protocol. Nine patients had additional donor-
specific antibodies and were treated with plasma exchange
and were therefore excluded from the study. The remaining
71 patients were treated with selective immunoadsorption
and included into the analysis. No patient was lost to
follow-up. The mean follow-up was 4.2 years. Fifty-two
(73%) recipients were men, 19 (27%) were women. The ma-
jority had blood groupO (64.7%). The blood group constel-
lations were as follows: 46 patients, A to O; one patient, AB
to O, eight patients, A to B; three patients, AB to A, two pa-
tients, AB to B, three patients, B to O; and eight patients B to
A. Themost frequent type of relationship between donor and
recipient was married couples, and there was a significantly
higher proportion of female donors (45, 63.4%) compared
to male donors (26, 36.6%). The mean donor age was 52.5
(±10.7) years, and themean recipient agewas 51.8 (±13.2) years.were both 97.2% at 5 years.
 Health, Inc. All rights reserved.
FIGURE 3. The rejection-free survival rate of the cohort with 18.3%
of the patients developed a biopsy-proven rejection within the
follow-up period.
© 2015 Wolters Kluwer Schiesser et al 1033Fifty (70%) recipients were on dialysis at the time of trans-
plantation, whereas 30% received a preemptive transplant.
Patient Survival, Graft Survival, and Graft Function
The Kaplan-Meier estimate for patient survival was 97.2%
at 5 years (Fig. 1A). The Kaplan-Meier estimates for death-
censored graft survival after 1, 2, and 5 years were excellent
with 100%, 98.6%, and 97.2%, respectively (Fig. 1B).
The estimated glomerular filtration rate (eGFR) calculated
by the chronic kidney disease epidemiology collaboration for-
mula after 1, 2, and 5 years were 54.05 mL per min (±16.03),
52.98 mL per min ( ±14.48), and 54.0 mL per min (±15.87), re-
spectively. The serum creatinine levels at 1, 2, and 5 years were
126 μmol/L (±39.2), 128 μmol/L (±35.9), and 129.4 μmol/L
(±54.6), respectively. The percentage of patients with a path-
ologic albumin-to-creatinine ratio or protein-to-creatinine
ratio over time is given in Figure 2.
Rejection Rate
Thirteen (18.3%) patients developed biopsy-proven acute
rejection. The Kaplan-Meier curve for rejection-free survival
is given in Figure 3. Among the 13 biopsy-proven acute rejec-
tion, three patients had a cellular rejection, whereas 10 had
an AMR. The cellular rejections could be treated successfully
in all but one case with methylprednisolone pulses. One pa-
tient needed antithymocyte globulin. Four patients with
AMR had to undergo therapeutic plasma exchange. One pa-
tient lost his graft because of early sepsis or caecum perfora-
tion and subsequent rejection because of immunosuppression
reduction. The majority of rejections occurred early at a
mean interval of 4.9 months after transplantation; six rejec-
tions occurred within the first month and seven within the
first 3 months. At the end of the follow-up period, 25% of
the patients were on a corticosteroid-free immunosuppres-
sion regimen.
Complications
The overall perioperative complication rate (<30 days)
was 26.8% according to the Clavien/Dindo classification.14
Seventeen percent of all patients experienced severe complica-
tions Grad III to IV requiring an intervention or a reoperation.
Among these, there were four patients with a septicemia, two
patients with a bleeding complication, two patients with a
ureteral complication, and four with a lymphocele. AllFIGURE 2. The proportion of patients (%) with proteinuria over time
and at the end of follow-up.
Copyright © 2015 Wolters Kluwer Hcomplications occurred exclusively after the transplantation
and not during the immunoadsorption period before the
transplantation. In the further follow-up, four patients devel-
oped cytomegalovirus (CMV) disease and 13 had BK viremia;
however, no polyomavirus nephropathy occurred. Two of 71
patients died during the follow-up period. One patient devel-
oped a severe donor-derived herpes simplex virus 2 infection
and lost his graft. In the further course, he developedmultiple
complications and died 199 days after transplantation froma
complicated pancreatitis. Another patient died 800 days
after transplantation from anE. coli sepsis with a functioning
graft. No complication (infection/fever) occurred during the
immunoadsorption therapy before transplantation.
Selective Immunoadsorption and Reuse of
the Columns
Seventy-one patients underwent antigen-specific immuno-
adsorption treatment. Four hundred twenty-nine immuno-
adsorption therapies were performed before transplantation
and 30 posttransplantation. The specific immunoadsorption
successfully lowered the antibody titers in all patients al-
lowing a subsequent transplantation. The median number
of immunoadsorptions performed before transplantation
was 5 (range, 3–18; Fig. 4A). Nine (12.7%) patients under-
went immunoadsorption after transplantation. The median
number of immunoadsorptions after transplantation was
zero (range, 0–11). The columns were successfully reused in
all centers. Overall, we used one to four columns per patient,
but only two patients needed more than three columns. We
performed a median of three (range, 1–12) immunoadsorp-
tions per column (Fig. 4B). At the introduction of the column
reuse protocol, we used more columns per patients also for
logistical reasons. One hundred fifty-one columns were used
for 459 immunoadsorptions. Using this strategy, we could
save 308 columns, which corresponds to 1,523,541 USD (av-
erage cost per column 4,946 USD). This corresponds to a
saving of 21,458 USD per transplantation.
At the beginning, we assessed the efficacy of the column re-
use by checking the antibody titers in the eluate after the col-
umn. Details about the first 57 column efficacy tests are given
in Table 1. Because the filter reuse efficacy was shown to be
reliable, we then focused only on the in vivo antibody titers
as a surrogate for the filter efficacy. Furthermore, we per-
formed a subgroup analysis for patients, who were treatedealth, Inc. All rights reserved.
FIGURE 4. A, the number of immunoadsorptions before and after transplantation. Themedian number of immunoadsorptions performed be-
fore transplantation was 5 (range, 3–18). The median number of immunoadsorptions after transplantation was zero (range, 0–11). B, the data
about immunoadsorption column reuse. Overall, we used one to four columns per patient and we performed a median of 3 (range, 1–12)
immunoadsorptions per column.
1034 Transplantation ■ May 2015 ■ Volume 99 ■ Number 5 www.transplantjournal.comwith filter reuse. Of the 71 patients, 54 patients (76%)
underwent immunoadsorption using filter reuse. A total of
394 immunoadsorption procedures were performed with
reused filters. The outcome did not differ from the remaining
patients.
The patient survival rate was 98% (95% confidence inter-
val [95%CI], 94% to 100%) in the filter reuse subgroup and
91% (95% CI, 75% to 100%) in the other subgroup
(P=0.418). The graft survival was 98% (95% CI, 94% to
100%) in the filter subgroup compared to 91% (95% CI,
75% to 100%) (P=0.435). The rate of acute rejection was
19% (10/53) in the filter subgroup (95% CI, 11% to 31%)
and 17% (3/18) (95% CI, 6% to 39%) in the other group
(odds ratio 1.13 with 95% CI, 0.29 to 5.86, P=0.870).
The complication rate was 30% in the filter reuse sub-
group (95% CI, 20% to 44%) and 22% (95% CI, 9% to
45%) in the other group (odds ratio 1.48 with 95% CI,
0.44 to 6.04, P=0.544). No septicemias and reactions to dis-
solved filter components similar to first-use syndrome were
observed in the filter reuse group.FIGURE 5. The course of the IgG (A) and IgM (B) titers before transpla
undetectable immunoglobulin titers are indicated in the boxes below the
Copyright © 2015 Wolters KluwerThe eGFR at 1, 2, and 5 years in the filter reuse subgroup
were 53.4±15.4 mL per min, 52.4±15.0 mL per min, and
52.7±16.2 mL per min, respectively. The eGFR did not differ
from the eGFR in the other subgroup at 1 and 2 years and at
the end of follow-up with values of 55.1±17.7 mL per min
(P=0.611), 55.2±12.6 mL per min (P=0.575), and 54±14.0 mL
per min (P=0.763). No patient treated with a reused filter
experienced an infectious complication at the time before
transplantation.
Course of Blood Group Antibody Titers and B Cells
The IgG and IgM titers were successfully lowered to anti-
body titers of less or equal 1:8 before transplantation using
specific immunoadsorption (Fig. 5A andB). Reuse of the immu-
noadsorption columns did not compromise the elimination
of the blood group antigens, and no patient was deferred
from transplantation because of insufficient lowering of anti-
A/B titers. The titers remained low in most of the patients
throughout the follow-up period. Only two patients presented
with an IgG or IgM titer ofmore than 1:8 during the follow-upntation and during the follow-up in a logarithmic scale. Patients with
graph. IgG, immunoglobulin G; IgM, immunoglobulin M.
 Health, Inc. All rights reserved.
© 2015 Wolters Kluwer Schiesser et al 1035period. The mean number of B cells was 98.6 cells/μL (normal
range) before transplantation and remained low at a mean of
16.4 cells/μL after 1 year.
DISCUSSION
This is the first report on a multicenter protocol reusing
specific immunoadsorption columns for ABO-incompatible
kidney transplantation. The protocol has been established
and approved by the Swiss ABO-incompatible kidney trans-
plantation group and has been standardized in all transplan-
tation centers across Switzerland. We have shown that the
protocol is efficient in reducing the antibody titers and is
safe to perform in clinical practice. The results of the multi-
center ABO-incompatible cohort are comparable to the results
of the available ABO-compatible data in the literature.1,16
and the Swiss Transplant Cohort Study established since
May 2008.
The reuse of the columns did not result in an increased rate
of acute rejection or inefficient elimination of blood group an-
tibodies.We observed that the anti-A/B antibody titers and the
peripheral B cell pool remained suppressed up to 1 year after
transplantation, similar to the findings of Tobian et al.17
The protocol for the column reuse was solid and could be
successfully used even in centers with small patient numbers.
The costs of the peritransplant treatment could therefore be
reduced substantially by eliminating the costs for additional
columns. Using this strategy, we saved the expenditure of
over one million Euros in this cohort, which corresponds to
a saving of approximately 17,000 Euros per transplantation.
This is an important factor in times, where reimbursement
for hospitals is becoming more and more restrictive.
In addition to cost savings, thismulticenter approach allowed
evaluation of protocol minimization. Our data suggest that pre-
operative treatment with intravenous immunoglobulin (IVIG)
and prophylactic postoperative immunoadsorption are not
necessary, which has already been shown by others.18
In conclusion, we have established a national protocol in-
cluding the reuse of specific immunoadsorption columns in
ABO-incompatible kidney transplantation. The protocol and
reuse of the columns proved to be efficient and safe and
allowed substantial cost savings while maintaining good out-
come results.
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